Management of Chronic Stable COPD

Slides:



Advertisements
Similar presentations
GOLD MANAGEMENT PLAN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Advertisements

ABCDABCD mMRC < 2 CAT 2 CAT > >2>2 RISK GOLD RISK Exacerbation TypeCharatteristicSpirometric classification Exacerbation Per.
COPD -Review of ‘At Risk Patient’
COPD Pathway and Discharge bundle
Michael W. Nash, MD Family Medicine Clinton County Rural Health Clinic Understanding COPD.
PREVENTING COPD EXACERBATIONS
GOLD Clasification Antonio Anzueto MD Professor Medicine University of Texas.
COPD Alison Boland StR Respiratory medicine. Aims & Objectives Overview of COPD Recap basic knowledge Update on COPD Know when to use nebulisers and home.
COPD Joshua Jewell. Epidemiology 8% of all individuals 10% age >40 6 th leading cause of death worldwide th in U.S. - >120,000 Expected 3 rd 2020.
Chronic obstructive pulmonary disease (COPD) Professor Bill MacNee
COPD Management of Stable COPD Shyam Rao May 2014.
Practice Support Program in COPD: South Okanagan Project COPD CARE Algorithm South Okanagan, Interior Health Patricia Rattee RRT, CRE Shannon Walker MD,
© 2013 Global Initiative for Chronic Obstructive Lung Disease
How can COPD Community Services reduce hospital admissions? Glenda Esmond Respiratory Nurse Consultant West Herts Community COPD Service.
COPD Patient and carers Therapies inc pulm rehab Intermediate care team Social Worker Respiratory Physician EAW/General Physician Case manager/ Community.
Medicines optimisation can help reduce COPD related hospital admissions and exacerbations - LCH MMT Approach Alison McMinn Respiratory Lead Pharmacist.
GOLD Update 2011 Rabab A. El Wahsh, MD. Lecturer of Chest Diseases and Tuberculosis Minoufiya University REVISED 2011.
COPD and Outreach Services Mandy Dickson Clinical Nurse Specialist Respiratory Outreach Service.
COPD Diagnosis & Management Anil Ramineni Specialist Respiratory Physiotherapist Community Respiratory Team.
Chronic Obstructive Pulmonary Disease Austin Paul K.
© IPCRG 2007 COPD -Management of stable disease WONCA meeting Istanbul October 2015 Svein Høegh Henrichsen Oslo, Norway.
Severe breathlessness
COPD Stage - 1 TREATMENT :
COPD? Where Are We Headed?
Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.
For 2010/ schools 58,000 girls 1st and 2nd year special schools home schooled May cohort September cohort Blitz and mop up An Audit of Discharges.
Survey of acute hospital resources for patients with COPD T McCarthy, M O’Connor, on behalf of the National COPD (Respiratory) Strategy Group Population.
GOLD 2017 major revision: Summary of key changes
Current management of COPD and when to refer?
Respiratory Initiatives: GOLD - ABCD, CAT Scores and myCOPD
Pulmonary Center of Excellence
Pulmonary Rehabilitation Primary Care Education Event 23/11/16
COPD 2003.
COPD.
Chronic Obstructive Pulmonary Disease(COPD)
COPD – Primary Care Update
Thank you for viewing this presentation.
COPD Pathway MDM (10new Or 8new 4 FU)
COPD PATHWAY AND PRESCRIBING POLICY IN LAMA options (stop SAMA):
COPD Report 5 Coles Lane, Oakington, Cambridge, CB24 3BA.
Medicines Management – COPD update for LPC Jyoti Saini Hema Patel
Reduced Quality of Life
RISK STRATIFICATION TOOL
GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (GOLD):
Assessing COPD in Primary Care
Treatment Strategies in Mild to Moderate COPD
COPD: One Patient’s Journey
بیماریهای مزمن انسدادی ریه COPD
Dual Bronchodilation in COPD: From Clinical Trial Evidence to Clinical Practice.
What Is the Role of Dual LAMA/LABA Bronchodilation in COPD Therapy in Light of New Clinical Data?
Volume 153, Issue 4, Pages (April 2018)
Community Health Pearl:
COPD Exacerbations UCI Internal Medicine Mini-Lecture
Components Mechanisms of action Outcomes
Long-Acting Agents in Severe COPD
COPD Exacerbation (1) C.L.I.P.S.
West Essex Frailty Pathway: COPD
Diagnosi della BPCO 1.
Dr Alia Ibrahim MD, KBIM, MRCP, KBRF
Gestione clinica della BPCO
Schematic overview of the suggested pharmacological management of chronic obstructive pulmonary disease (COPD). Schematic overview of the suggested pharmacological.
And WHY does it matter which label?
Community Respiratory Specialist Service
COPD in West Essex Dr.Angus Henderson Prof.Mike Roberts
Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.
GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (GOLD)
PALLIATIVE CARE FOR COPD PATIENTS:
Nottingham City Care Integrated Respiratory Service and Home Oxygen Service Zoe Styles Senior Physiotherapist.
Management of COPD: Lost Opportunities?
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) ABCD scheme for classifying patients with COPD with separate appraisal of air-flow limitation.
Presentation transcript:

Management of Chronic Stable COPD *Based on GOLD Risk Stratification 2019 Category Symptoms Risk Suggested Treatment Co- Management ALL Patients Short-acting Bronchodilator (rescue) Self-Management Education Smoking cessation Increase Exercise tolerance Influenza and Pneumococcal vaccination A Less symptomatic Mild or infrequent symptoms, breathless with strenuous exercise or when hurrying on level ground or walking up a slight hill Low Risk mMRC 0-1 or CAT <10, AND 0 to 1 exacerbations a year not leading to hospital admission Pharmacologic: First choice: LAMA or LABA Primary Care B More symptomatic: Moderate to sever symptoms (i.e. Patient has to walk more slowly that others of the same age due to breathlessness, has to stop to catch breath when walking on level ground) Pharmacologic Second Choice: LABA/ICS combination in patients eos ≥ 300 or eos ≥100 AND ≥ 2 moderate exacerbations/ 1 hospitalization Non-Pharmacologic: Pulmonary Rehab C High Risk mMRC ≥ 0-1 or CAT ≥ 10, AND ≥ 2 exacerbations a year OR ≥ 1 leading to hospitalization First choice: LAMA Consider Referral to Pulmonary Medicine for Co-Management D First choice: LAMA: Initial therapy LAMA/LABA: Preferred if highly symptomatic (i.e. CAT >20) LABA/ICS: Preferred if eos ≥300 Second choice: LAMA/LABA/ICS: Preferred as escalation of therapy if eos ≥ 100 with predominant exacerbations OR if dyspnea is not controlled by LABA/ICS Primary Care Referral to Pulmonary Medicine for Co- Management Palliative care referral for COPD Patients with more than 1 hospitalization a year for COPD Exacerbation

Hospital Follow Up and Referral Pathways for COPD Hospital Follow Up for Acute Exacerbation of COPD Phone Call within 24 hours of Discharge Office Visit within 3- 7 days with PCP Refer to Pulmonary if meets criteria Arrange for Pulmonary follow up, if established patient Refer to Palliative Care, per criteria below Referral Pathways Pulmonary to Consult and Co- Manage: Severe COPD, GOLD Stage D Pulmonary to Consult and Co- Manage: If 2 or more admissions per year for AE-COPD Palliative care consult: If ≥ 1 hospitalizations per year for COPD